- CASTRES, France, February 3, 2016 /PRNewswire/ --
Pierre Fabre Laboratories, the 2nd independent French pharmaceutical laboratory, has announced the launch of the Pierre Fabre Fund for Innovation, an original open-innovation initiative. The Pierre Fabre Fund for Innovation is intended for bio-pharmaceutical companies, start-ups and research laboratories (public or private) specialising in oncology or in dermatology, two of Pierre Fabre R&D's priority therapeutic areas.
The research projects that will be supported will either be fewer than 24 months away from moving from the pre-clinical stage to clinical development, or will be in the early stage of clinical development. The Pierre Fabre Fund for Innovation will offer a range of differing types of partnership: providing Pierre Fabre's skills across all of the medicine's value chain, co-funding research programmes, acquiring a minority shareholding, or licence agreements. The combination of several types of support will also be a possibility.
Open to all international partnership opportunities, the primary ambition of the Pierre Fabre Fund for Innovation is to assist French and European innovators. The skills that Pierre Fabre can offer these innovators include pharmacology, new chemical entities, biotherapies, immunotherapy, translational medicine, pre-clinical and clinical development, the manufacturing of clinical batches and market access, as well as regulatory and business strategy.
Laurent Audoly, Head of Pharmaceutical R&D, will oversee the operational direction of the Pierre Fabre Fund for Innovation. Deliberately tight governance, positioned at the company's highest level, will allow a swift and personalised response to project managers.
To get in contact, please visit:http://www.pierre-fabre.com, section "Partenariats & Open Innovation" Or: email@example.com@pierre-fabre.com,firstname.lastname@example.org, +33-(1)-49-10-83-84